Skip to main content
CANF logo

Can-Fite BioPharma Ltd.

CANFNYSEAMERICANHealthcareBiotechnology

$1.76Today:- (-)1Y −81.54%

As of Oct 16, 2026 close

Market cap
$6.87M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$1.90$12.30
Volume (live)
-
Avg. volume (3M)
54.92K

Can-Fite BioPharma (CANF) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Can-Fite BioPharma used $8.95M of cash in operating activities and spent $2.00K on capital expenditures. That left free cash flow of −$8.95M.

Can-Fite BioPharma Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Can-Fite BioPharma Ltd. (CANF) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017
Period endingDec 2025Mar 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
Operating Activities
Net Income-9.83-7.88-7.88-7.63-10.17-12.62-14.44-12.63-6.57-4.98
Depreciation & Amortization0.020.010.010.020.010.010.010.010.010.02
Deferred Income Tax0.000.00-0.000.00-0.090.010.210.000.28
Stock Based Compensation0.340.360.360.260.260.470.360.390.540.20
Change in Working Capital0.43-0.27-0.27-0.94-1.302.432.001.191.13-2.45
Change in Accounts Receivable0.000.00-0.110.180.000.132.730.27-0.85-1.16
Change in Inventory0.000.00-0.000.000.001.27-0.320.130.00
Change in Accounts Payable0.680.190.19-0.47-0.060.97-1.601.090.64-0.96
Change in Other Working Capital0.04-0.460.030.17-1.24-0.05-0.400.151.22-0.32
Other Operating Activities0.040.140.11-0.220.40-0.050.000.000.73-2.59
Net Cash from Operating Activities-8.95-7.64-7.64-8.44-10.80-9.86-12.06-10.83-4.16-9.52
Investing Activities
Capital Expenditures0.000.000.000.00-0.01-0.01-0.030.00-0.03-0.01
Purchases of Investments0.000.001.500.500.00-14.500.000.000.000.00
Sales/Maturities of Investments0.000.001.500.500.000.000.000.000.00-0.02
Other Investing Activities0.001.50-0.509.510.000.00-0.250.00-0.02
Net Cash from Investing Activities0.001.501.500.509.50-14.51-0.03-0.25-0.03-0.03
Financing Activities
Debt Repayment0.000.00-0.000.000.000.00-0.030.000.00
Common Stock Issued9.646.716.719.140.0020.4617.6810.174.394.47
Other Financing Activities0.000.00-0.51-0.390.00-1.310.000.030.000.00
Net Cash from Financing Activities9.646.716.719.140.0020.4617.6810.174.394.88
Summary
Effect of Forex Changes on Cash0.01-0.02-0.020.10-0.110.03-0.020.00-0.09-0.81
Net Change in Cash0.700.550.551.30-1.41-3.915.57-0.920.11-5.48
Cash at Beginning of Period4.834.284.282.984.398.272.703.623.518.98
Cash at End of Period5.534.834.834.282.984.398.272.703.623.50
Free Cash Flow-8.95-7.64-7.64-8.44-10.81-9.87-12.09-10.84-4.19-9.53
Supplemental Disclosures
Interest Paid-----0.020.02---

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Can-Fite BioPharma Cash Flow

What is Can-Fite BioPharma's free cash flow?

Can-Fite BioPharma had negative free cash flow of $8.95M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$8.95M minus $2.00K of capital expenditures.

How much does Can-Fite BioPharma spend on capital expenditures?

Can-Fite BioPharma spent $2.00K on capital expenditures in fiscal 2025, compared with $5.00K a year earlier.

Does Can-Fite BioPharma pay dividends or buy back shares?

Can-Fite BioPharma's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition